Israel Fact of the Week
from the A-Team

US Department Buys Israeli Burns Treatment
Niva Goldberg, Jewish Business News (30 Sep 15)

The US Biomedical Advanced Research & Development Authority (BARDA) – part of the US Department of Health – has awarded a $112 million contract to Israel’s MediWound. BARDA will use MediWound’s product NexoBrid – a topical treatment – in major incidents, to remove dead tissues from medium to severe burns. BARDA will also help MediWound finance its FDA approval for NexoBrid.

BARDA, within the Office of the Assistant Secretary for Preparedness and Response in the US Department of Health and Human Services, provides an integrated, systematic approach to the development and purchase of the necessary vaccines, drugs, therapies, and diagnostic tools for public health medical emergencies.

The Emergency Use Authorization authority allows the FDA to help strengthen the nation’s public health protections against chemical, biological, radiological, & nuclear threats by facilitating the availability and use of medical countermeasures needed during public health emergencies.

Following this US federal funding, some of the $70 million raised on NASDAQ by MediWound in March 2014, can now be used for the development of other products.

Click here for the full story.